 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
10 News |  |
- LM-030 / Novartis, Lifemax Healthcare
[VIRTUAL] Rationale and design for the Kallikrein Inhibitor in Netherton Syndrome (KINS) pivotal clinical trial () - Jul 1, 2020 - Abstract #SID2020SID_494;
We summarize the Kallikrein Inhibitor in Netherton Syndrome (KINS) study, the first Phase 2/3, multicenter, randomized, double-blind, vehicle-controlled trial to evaluate the safety, efficacy and tolerability of a novel topical therapeutic (LM-030) in NS patients...The KINS study, targeted for initiation in the US and EU in mid-2020, will enroll over 100 patients. Additional design details will be presented in the presentation.
- LM-030 / Novartis, Lifemax Healthcare
Phase classification: CBPR277X2101: A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (clinicaltrials.gov) - Jun 12, 2014
P1, N=12, Completed, Sponsor: Novartis Pharmaceuticals
Additional design details will be presented in the presentation. Phase classification: P1/2 --> P1
- LM-030 / Novartis, Lifemax Healthcare
Trial primary completion date: CBPR277X2101: A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (clinicaltrials.gov) - May 19, 2014
P1, N=12, Completed, Sponsor: Novartis Pharmaceuticals
Phase classification: P1/2 --> P1 Trial primary completion date: Mar 2014 --> Feb 2014
- LM-030 / Novartis, Lifemax Healthcare
Trial completion date: CBPR277X2101: A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (clinicaltrials.gov) - May 19, 2014
P1, N=12, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2014 --> Feb 2014 Trial completion date: Mar 2014 --> Feb 2014
- | LM-030 / Novartis, Lifemax Healthcare
Trial completion: CBPR277X2101: A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (clinicaltrials.gov) - May 19, 2014
P1, N=12, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2014 --> Feb 2014 Active, not recruiting --> Completed
- ||| LM-030 / Novartis, Lifemax Healthcare
Enrollment change: CBPR277X2101: A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (clinicaltrials.gov) - May 19, 2014
P1/2, N=85, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=65 --> 85
- ||| LM-030 / Novartis, Lifemax Healthcare
Enrollment closed: CBPR277X2101: A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (clinicaltrials.gov) - Sep 2, 2012
P1/2, N=85, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=65 --> 85 Recruiting --> Active, not recruiting
- ||||| LM-030 / Novartis, Lifemax Healthcare
New P1/2 trial: CBPR277X2101: A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (clinicaltrials.gov) - Aug 31, 2011
P1/2, N=85, Active, not recruiting, Sponsor: Novartis Pharmaceuticals